Mechanistically, it inhibits the PI3K/AKT/mTOR and MAPK/ERK signaling pathways and downregulates pro-inflammatory cytokines, supporting its potential as a multi-targeted therapeutic candidate for papillary thyroid carcinoma. Here, AKT1 is linked to thyroid gland papillary carcinoma.